Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)

v3.10.0.1
Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2018
Notes Tables  
Schedule of Franchisor Disclosure [Table Text Block]
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
Franchised clinics:   2018   2017   2018   2017
Clinics open at beginning of period    
365
     
336
     
352
     
309
 
Opened or purchased during the period    
10
     
6
     
25
     
35
 
Acquired during the period    
-
     
-
     
(1
)    
-
 
Closed during the period    
(1
)    
-
     
(2
)    
(2
)
Clinics in operation at the end of the period    
374
     
342
     
374
     
342
 
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
Company-owned or managed clinics:   2018   2017   2018   2017
Clinics open at beginning of period    
48
     
47
     
47
     
61
 
Opened during the period    
-
     
-
     
-
     
-
 
Acquired during the period    
-
     
 
     
1
     
-
 
Closed or sold during the period    
-
     
-
     
-
     
(14
)
Clinics in operation at the end of the period    
48
     
47
     
48
     
47
 
                                 
Total clinics in operation at the end of the period    
422
     
389
     
422
     
389
 
                                 
Clinic licenses sold but not yet developed    
126
     
105
     
126
     
105
 
Executed letters of intent for future clinic licenses    
12
     
5
     
12
     
5
 
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
    2018   2017   2018   2017
        (as adjusted)       (as adjusted)
Net loss   $
(151,803
)   $
(431,705
)   $
(581,486
)   $
(3,219,232
)
                                 
Weighted average common shares outstanding - basic    
13,727,712
     
13,262,032
     
13,646,599
     
13,144,764
 
Effect of dilutive securities:                                
Unvested restricted stock, stock options and warrants    
-
     
-
     
-
     
-
 
Weighted average common shares outstanding - diluted    
13,727,712
     
13,262,032
     
13,646,599
     
13,144,764
 
                                 
Basic and diluted loss per share   $
(0.01
)   $
(0.03
)   $
(0.04
)   $
(0.24
)
Anti-Dilutive shares:                
    Three Months Ended   Nine Months Ended
    September 30,   September 30,
    2018   2017   2018   2017
     Unvested restricted stock    
51,134
     
63,700
     
51,134
     
63,700
 
     Stock options    
960,213
     
1,011,686
     
960,213
     
1,011,686
 
     Warrants    
90,000
     
90,000
     
90,000
     
90,000
 
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]
    As of December
31, 2017
  Adjustments Due
to ASC 606
Adoption
  As of December
31, 2017
ASSETS  
(as reported)
 
 
 
(as adjusted)
Current assets:                        
Deferred franchise costs - current portion   $
484
 
  $
14
    $
498
 
Total current assets    
6,657
 
   
14
     
6,671
 
Deferred franchise costs, net of current portion    
813
 
   
1,500
     
2,313
 
Deposits and other assets    
612
 
   
12
     
623
 
Total assets   $
16,910
 
  $
1,526
    $
18,436
 
                         
LIABILITIES AND STOCKHOLDERS' EQUITY                        
Current liabilities:                        
Deferred franchise revenue - current portion   $
1,686
 
  $
308
    $
1,994
 
Other current liabilities    
49
 
   
104
     
153
 
Total current liabilities    
4,967
 
   
412
     
5,379
 
Deferred revenue, net of current portion    
4,693
 
   
4,859
     
9,553
 
Total liabilities    
12,011
 
   
5,271
     
17,283
 
Stockholders' equity:                        
Accumulated deficit    
(32,259
)
   
(3,745
)    
(36,004
)
Total stockholders' equity    
4,899
 
   
(3,745
)    
1,153
 
Total liabilities and stockholders' equity   $
16,910
 
  $
1,526
    $
18,436
 
    Three Months Ended
September 30, 2017
  Three Months Ended
Adjustments Due
to ASC 606
Adoption
  Three Months Ended
September 30, 2017
    (as reported)       (as adjusted)
Revenues:            
Franchise fees   $
230
    $
152
    $
382
 
Regional developer fees    
259
     
(160
)    
99
 
Total revenues    
6,546
     
(8
)    
6,538
 
Cost of revenues:                        
Franchise cost of revenues    
716
     
20
     
736
 
Total cost of revenues    
819
     
20
     
839
 
Loss from operations    
(378
)    
(28
)    
(406
)
Loss before income tax expense    
(368
)    
(28
)    
(396
)
Net loss and comprehensive loss   $
(404
)   $
(28
)   $
(432
)
                         
Loss per share:                        
Basic and diluted loss per share   $
(0.03
)   $
(0.00
)   $
(0.03
)
    Nine Months Ended
September 30, 2017
  Nine Months Ended
Adjustments Due
to ASC 606
adoption
  Nine Months Ended
September 30, 2017
    (as reported)       (as adjusted)
Revenues:                        
Franchise fees   $
1,037
    $
4
    $
1,041
 
Regional developer fees    
456
     
(194
)    
262
 
Total revenues    
18,235
     
(189
)    
18,045
 
Cost of revenues:                        
Franchise cost of revenues    
2,104
     
(32
)    
2,071
 
Total cost of revenues    
2,332
     
(32
)    
2,299
 
Loss from operations    
(2,949
)    
(157
)    
(3,106
)
Loss before income tax expense    
(2,983
)    
(157
)    
(3,140
)
Net loss and comprehensive loss   $
(3,062
)   $
(157
)   $
(3,219
)
                         
Loss per share:                        
Basic and diluted loss per share   $
(0.23
)   $
(0.01
)   $
(0.24
)